Vaginal Atrophy: The 21st Century Health Issue Affecting Quality of Life

Stenberg A, Heimer G, Ulmsten U, et al. Prevalence of genitourinary and other climacteric symptoms in 61 year old women. Mauritas. 1996;24:31-36.
Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61:3090-3096. Abstract
Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med. 2005;2:154-165. Abstract
Simuniæ V, Banoviæ I, Ciglar S, Jeren L, Paviciæ Baldani D, Sprem M. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet. 2003;82:187-197. Abstract
Bachmann GA, Ebert GA, Burd ID. Vulvovaginal complaints. In Lobo RA ed. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:195-201.
Semmens JP, Tsai CC, Semmens EC, et al. Effects of estrogen therapy on vaginal physiology during menopause. Obstet Gynecol. 1985;66:15-18. Abstract
North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause. 2007;14:355-369. Abstract
Sarrel P, Foddy J, McKinnon JB. Investigation of human sexual response using a cassette recorder. Arch Sex Behav. 1977;6:341-348. Abstract
Van Der Laak JA, De Bie LM, De Leeuw H, De Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446-451. Abstract
Gordoski G, Arias R. Atrophic vaginitis and estrogen treatment. Medscape. 2007. Available at: http://www.medscape.com/viewprogram/7489 Accessed August 27, 2007.
Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC trial after completion of 5 years adjuvant treatment for early breast cancer. Breast Cancer Res Treat. 2006;100:273-284. Abstract
Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6:45-52. Abstract
Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8:83-92. Abstract
Nachtigall L, Nachtigall M, Goren J, Lowenstein J. Update on vaginal atrophy. Menopause Management. Sept/Oct. 2005;17-20.
Nactigall L. Vaginal estrogen in the controversial patient. Menopause Management. 2006;March/April:19-22.

processing....

Conclusion

all cause ovarian dysfunction and lead to vaginal atrophy. For example, patients with breast cancer treated with an aromatase inhibitor have been found to experience significant vaginal dryness and painful coitus.^[11]Women are living longer, healthier, productive lives, and are now expected to live about one third of their lives after menopause. Vaginal atrophy and related symptoms associated with natural or induced menopause, cancer treatment, lactation, medications, or chronic conditions warrant prompt identification, correct diagnosis, and optimal treatment. A variety of safe, effective treatment options are available. Careful assessment of the needs of individual needs and preference may facilitate successful treatment outcome. Sexuality can be enhanced, urologic functioning significantly improved, and quality of life positively affected when vaginal atrophy is recognized and treated.

Supported by an independent educational grant from NovoNordisk